Neuroblastoma (NBL) is the most common solid tumor in infants and accounts for 15% of all pediatric cancer deaths. Several risk factors predict NBL outcome: age at the time of diagnosis, stage, chromosome alterations and MYCN (V-Myc Avian Myelocytomatosis Viral Oncogene Neuroblastoma-Derived Homolog) amplification, which characterizes the subset of the most aggressive NBLs with an overall survival below 30%. MYCN-amplified tumors develop exceptional chemoresistance and metastatic capacity. These properties have been linked to defects in the apoptotic machinery, either by silencing components of the extrinsic apoptotic pathway (e.g. caspase-8) or by overexpression of antiapoptotic regulators (e.g. Bcl-2, Mcl-1 or FLIP). Very little is known on the implication of death receptors and their antagonists in NBL. In this work, the expression levels of several death receptor antagonists were analyzed in multiple human NBL data sets. We report that Lifeguard (LFG/FAIM2 (Fas apoptosis inhibitory molecule 2)/NMP35) is downregulated in the most aggressive and undifferentiated tumors. Intringuingly, although LFG has been initially characterized as an antiapoptotic protein, we have found a new association with NBL differentiation. Moreover, LFG repression resulted in reduced cell adhesion, increased sphere growth and enhanced migration, thus conferring a higher metastatic capacity to NBL cells. Furthermore, LFG expression was found to be directly repressed by MYCN at the transcriptional level. Our data, which support a new functional role for a hitherto undiscovered MYCN target, provide a new link between MYCN overexpression and increased NBL metastatic properties.
Neuroblastoma (NBL) is the most common solid tumor of infancy, accounting for 15% of all pediatric cancer deaths. These tumors are very heterogeneous, with a clinical course ranging from spontaneous regression to aggressive behavior. Several risk factors predict NBL outcome: INSS (International Neuroblastoma Staging System) tumor stage, age at diagnosis, INPC (International Neuroblastoma Pathology Classification) classification, DNA ploidy and MYCN (V-Myc Avian Myelocytomatosis Viral Oncogene Neuroblastoma-Derived Homolog) oncogene amplification, which characterizes the subset of most aggressive NBLs with overall survival below 30%. [1] [2] [3] MYCN-amplified tumors are characterized by exceptional chemoresistance and metastatic capacity. These properties have been linked to defects in the apoptotic arsenal, either by overexpression of the antiapoptotic regulators of the mitochondrial pathway (e.g. Bcl-2, Mcl-1) 4, 5 or by alteration of components of the extrinsic apoptotic pathway (e.g. caspase-8). [6] [7] [8] In fact, there is evidence that the extrinsic pathway may serve as a checkpoint to guard cells from MYCN-initiated tumorigenesis as MYCN-elevated levels sensitize NBL cells to death receptor (DR)-induced cell death, either by TRAIL, TNFa or FasL stimuli. 9 To date, the main mechanism underlying the lack of DR-induced apoptosis in MYCN-amplified tumors has been methylation of the caspase-8 promoter, which blocks its expression and renders cells resistant to DR-induced cell death. 7, 10 However, the correlation between MYCN amplification and caspase-8 silencing in tumor samples remains controversial; other authors showed the inactivation of caspase-8 to be independent of MYCN amplification and NBL prognosis. 6 As MYCN amplification and caspase-8 silencing may not occur simultaneously, alternative resistance mechanisms must exist, which either block DR-induced cell death or switch DR signaling to alternative functions. DR activity can also be modulated by DR antagonists, which have been poorly characterized in the context of NBLs. The present work sought to analyze the role of DR antagonists in NBL and their contribution to the oncogenic properties of NBL cells. Several DR antagonists were found to be differentially expressed in the highest-risk NBL tumors, namely stage 4 MYCN-amplified NBLs. Among these, FAIM2 (Fas apoptosis inhibitory molecule 2), most commonly referred to as Lifeguard (LFG), correlates best with worse overall survival of NBL patients. Furthermore, we show that MYCN is able to repress directly LFG expression, which results in increased oncogenic properties such as augmented sphere formation, decreased adhesion and enhanced migration. Collectively, our results demonstrate a previously unappreciated role of LFG, and support a new target for therapeutic intervention against high-risk NBL.
Results
The DR antagonist LFG is downregulated in high-risk NBL. The mRNA expression levels of antiapoptotic genes known to modulate the extrinsic pathway in the neural lineage were analyzed in independent human expression and prognostic NBL data sets. Few DR modulators were consistently altered in different NBL data sets. Table 1 shows the fold change variation between stage 4 MYCN-amplified tumors versus the rest of stages present in the respective study (i.e. stages 1, 3 and 4 without MYCN amplification). PEA15, CFLAR/FLIP and LFG were downregulated in advanced stages of the disease. In particular, the highest differential expression was found in stage 4 MYCN-amplified patients, the group of NBLs with the worst prognosis ( Figure 1a ). Whether the differences in gene expression could be associated with patient outcome was also analyzed. Notably, only low expression levels of LFG were associated with worse overall survival ( Figure 1b and Table 1) . Moreover, the association between LFG levels and patient survival was maintained in MYCN non-amplified tumor subsets (Supplementary Figure 1) . These differences in LFG expression levels were then validated in an independent cohort of 38 primary tumor samples obtained at the Vall d'Hebron Hospital (Supplementary Table 1 ). Quantitative real-time PCR (qPCR) expression analysis revealed a significant reduction in LFG levels in stage 4 and MYCNamplified tumors (Figure 1c ). Western blot analyses confirmed that differences in mRNA expression were also found at the protein level (Figure 1d ). In summary, we conclude that LFG is the DR antagonist with the highest differential expression and association with patient outcome in high-risk NBL.
LFG is associated with NBL differentiation. When LFG levels were correlated with a number of clinicopathologic variables (i.e. age at diagnosis, site of primary tumor, site of metastasis and histology), LFG expression was found to be closely associated with tumors presenting unfavorable histology (P ¼ 0.0041) and MYCN amplification (P ¼ 0.0121), which are often undifferentiated tumors 11 (Figure 2a and  Supplementary Table 2 ). With a view to ascertain the association between tumor differentiation and LFG expression, we sought to characterize LFG levels in the different status of NBL cell differentiation. On the one hand, all-trans retinoic acid (RA)-mediated differentiation of NBL cell lines increased LFG at mRNA and protein levels (Figures 2b and c) . TRKB was used as a neuronal differentiation marker 12 to confirm the differentiation response of the NBL cell lines to the RA treatment. On the other hand, LFG levels were analyzed in cells cultured in neurosphere formation medium (serum-free and supplemented with EGF/FGF2), which mimics undifferentiated status of NBL cells. 13, 14 When NBL cell lines were seeded in neurosphere medium, cells formed non-adherent spheres. LFG was found to be downregulated in sphere medium-cultured cells compared with cells cultured in standard conditions (P ¼ 0.0286 for SK-N-BE(2) and IMR-5; P ¼ 0.0294 for IMR-32) (Figure 2d ). We conclude that LFG expression associates with the differentiation status of NBL cells.
Reduction of LFG levels modulates proliferation, adhesion and migration of NBL cells. To assess the role of LFG in NBL oncogenic properties, loss-of-function experiments were performed using two different short hairpin (sh)RNA targeting LFG (Figure 3a ). Both shLFG constructs FC (P-value) GSE16237
Worse if (P-value) GSE16476
Worse if (P-value) Oberthuer lab (Figure 3b ). The most efficient downregulation was achieved by shLFG, which was used for the following experiments. Cell adhesion assays showed that shLFG-transduced cells exhibit around 50% reduction in adhesion to adherent plates compared with scrambled (Scr)-infected cells (P ¼ 0.0286 for SH-SY5Y and P ¼ 0.0043 for CHLA-90 cells) (Figure 3c ). Moreover, when NBL cells were seeded at low density, loss of LFG increased non-adherent growth compared with the Scr shRNA ( Figure 3d ). More than 10% of shLFG cells were able to form viable spheres when they were seeded at low density in Dulbecco's modified Eagle's medium (DMEM) supplemented with 15% fetal bovine serum (FBS), whereas o4% of control cells did so (P ¼ 0.0066). Furthermore, shLFG-infected cells showed a fourfold increased migration through the 8 mm-transwell polycarbonate inserts (P ¼ 0.0191) (Figure 3e ). The impact of these properties was further evaluated in vivo. SH-SY5Y cells (shLFG or shScr) were injected into the flank of female NMRI-Foxn1nu/Foxn1nu mice. Tumors appeared Figure 2) . The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis 15, 16 of genes differentially expressed in response to LFG knockdown revealed a reproducible modulation of genes mainly involved in cancer pathways and adhesion processes (Figure 5a ). Functional annotation analysis showed a remarkable modulation of genes implicated in focal adhesion, cell adhesion and adherent junctions (Figure 5b ), which supported an active role of LFG in the tumorigenic properties of NBL cells. Array data were validated by qPCR for FGF14, STK36, BCL2, RAP1A, TJP1, ITGA9 and LFG (Figure 5c ).
LFG expression is directly modulated by MYCN. As LFG levels were significantly lower in MYCN-amplified tumors, we sought to determine whether MYCN participates in LFG repression. Our first approach consisted in using the SHEP MYCN-inducible Tet21N cell line, which constitutively overexpresses MYCN under the control of a tetracyclineresponsive repressor element. 17 Doxycycline treatment of Tet21N resulted in a differentiated phenotype (Figure 6a ) and reduced MYCN expression with a concomitant time-dependent upregulation of LFG, both at the mRNA and protein level (Figure 6b) . Furthermore, the same result was obtained when MYCN was silenced using an inducible shRNA in an independent MYCN-amplified cell line such as IMR-32 (Supplementary Figure 4) . To address whether MYCN represses LFG directly, a chromatin immunoprecipitation (ChIP) data set was examined for MYCN binding in Tet21N cells with and without doxycycline treatment. 18 A high confidence MYCN-binding peak was identified in the LFG proximal promoter that disappeared when MYCN expression was repressed by doxycycline treatment (Figure 6c) .
MYCN-mediated transcription repression is now considered to be at least as important as transcription activation. 19 However, the repressing mechanisms remain unclear. It has 
Discussion
Alterations of key elements of the apoptotic pathway have been shown to be determinant in the outcome of NBLs. While characterization of the mitochondrial or intrinsic pathway elements has been extensive, limited attention to the components of the extrinsic or DR pathway has been paid. The most characterized element of the extrinsic pathway is caspase-8, which is lost in B70% of NBLs. 6, 20 Loss of caspase-8 has been shown to prevent DRinduced apoptosis [21] [22] [23] and potentiate NBL metastasis. 24, 25 However, caspase-8 can also be prometastatic if other components of the apoptotic machinery are compromised. 26 Whether other modulators of the intrinsic pathway can impact similarly to caspase-8 in NBL behavior remain understudied.
Here, we have analyzed the expression of several DR antagonists in multiple NBL data sets and found that LFG was the most differentially expressed DR antagonist in MYCNamplified tumors. LFG low levels were also found to correlate with worse overall survival. LFG was originally reported to be expressed exclusively in the nervous system and upregulated during the development of rat sciatic nerve. 27 Primary functional analyses revealed that LFG is able to antagonize FasL but not TNFa-induced cell death in T cells. 28 We and others confirmed that LFG is essential to prevent Fas-induced apoptosis in neuronal cells 29 by clustering with Fas receptor and blocking caspase-8 activation. 30 Recently, an alternative LFG function has been proposed. Merianda and co-workers 31 have demonstrated that LFG localization in axons is sufficient to support axonal growth in dorsal root ganglionar cells, thereby indicating that LFG may have DR antagonistindependent functions. Alternative functions for other DR antagonists are rare but not unique. In fact, the antiapoptotic protein PEA15 has also been linked to NBL prognosis. High levels of this protein correlate with favorable clinical features. PEA15 was shown to block NBL migration through the inhibition of ERK/RSK2 signaling, suggesting a metastatic limiting role in the progression of NBL. 32 Similar to PEA15, loss of LFG potentiates cell detachment, adherence-independent growth, migration and metastasis. However, the mechanism seems to be quite different. LFG knockdown impacted indirectly the modulation of cell adhesion and some epithelial-to-mesenchymal (EMT) genes (Supplementary Figure 3) . One example is ITGA9, which is found to be downregulated in shLFG-infected cells. ITGA9 has been shown to be essential for the adhesion of rhabdomyosarcoma cells. 33 Other prometastatic integrins were found to be upregulated (e.g. ITGAV, ITGB1). For example, overexpression of ITGAV has been found to correlate with metastasis of laryngeal, 34 hypopharyngeal squamous cell carcinomas 35 and colorectal cancer. 36 Moreover, ITGAV knockdown decreased proliferation and increased apoptosis in Hep-2 carcinoma cells. 35 Several tight-junction (TJ) genes were also downregulated (e.g. TJP1). Loss of cohesion of the TJ structure can lead to invasion and ultimately to the metastasis of cancer cells. 37 Regarding the EMT-related genes, we have found upregulation of TWIST1 upon LFG knockdown and also an inverse correlation in human samples ( Supplementary  Figures 3a and b) . TWIST1 is an important EMT and metastasis promoter gene, 38 which has been recently found to to be overexpressed in MYCN-amplified NBL. 39 By contrast, ERBB3 and KRT19 genes were found to be reduced in NBL cells infected with shLFG and downregulated in NBL human samples with low levels of LFG. ERBB3 belongs to the epidermal growth factor receptor family and participates in the activation of proliferation 40 and differentiation pathways, 41 whereas KRT19 is a member of the keratin family and participates in the organization of the cytoskeleton. 42 The expression of KRT19 or ERBB3 was found to be low in patients with poor prognosis. 39 Other genes such as FGF14, STK36 or BCL2 may contribute in a different manner to the metastatic process. STK36 is a serine/threonine kinase that has an important role in the activation of the sonic hedgehog pathway, reported to be essential for NBL proliferation and tumor growth. 43 The upregulation of BCL2 may also contribute to inhibit apoptosis when cells grow in anchorage-independent conditions. Furthermore, we provide evidence that low expression of LFG is not a mere association with the differentiation status of the cell, but it is actively repressed by the MYCN oncogene. MYCN encodes a protein with a basic helixloop-helix domain known to be a transcriptional regulator of genes controlling cell cycle and proliferation, cell invasion, angiogenesis and cell survival and death pathways (reviewed in Westermark et al. 11 ). MYCN has been shown to participate in NBL metastasis by direct or indirect repression of integrin subunits altering cell-matrix or cell-cell interactions 44 or repressing Caveolin-1, whose downregulation elicits anchorage-independent growth and tumor formation. 45 We show that repression of LFG impacts on the expression of several molecules that participate in cell adhesion processes, recapitulating some of the MYCN reported effects.
In summary, our results provide a new link between MYCN amplification and early steps of NBL metastasis, and the participation of LFG in unprecedented functions such as cell adhesion, anchorage-independent growth and migration.
Materials and Methods Reagents. Unless otherwise indicated, all reagents were purchased from Sigma-Aldrich (Barcelona, Spain). 5-Aza-2'-deoxycytidine was purchased from Calbiochem (San Diego, CA, USA). Gene expression data of human samples (GSE16476 48 and Oberthuer lab data set from Oncogenomics database) were used to generate Kaplan-Meier survival analysis.
Human samples. Primary tumor tissue samples from 38 NBL patients enrolled at the Vall d'Hebron Hospital (Barcelona, Spain) were obtained immediately after surgery and snap frozen in liquid nitrogen and stored at À 80 1C until processing. Tumors were examined by the pathologist to confirm NBL diagnosis and the presence of at least 80% of tumor tissue sample and histopathologic classification. All patients gave written informed consent.
Gene expression analysis by qPCR. Total RNA was extracted from NBL cell lines and tumor samples using the RNeasy Mini Kit (Qiagen, Las Matas, Spain). Between 0.5 and 1 mg of total RNA was retrotranscribed using High Capacity RNA-to-cDNA Kit (Applied Biosystems, Alcobendas, Spain). Gene expression analyses were performed using the LFG, TRKB, FGF14, STK36, BCL2, RAP1A, TJP1 and ITGA9 Taqman probes. Unless otherwise indicated, all expression analysis were normalized versus 18S housekeeping gene. MYCN expression was performed with SYBR green (Applied Biosystems) and normalized against L27 using the following primers: MYCN -forward, 5 heat-inactivated FBS, 20 U/ml penicillin and 20 mg/ml streptomycin. SK-N-BE(2) and CHLA-90 were maintained in Iscove's modified Dulbecco's medium, supplemented with 20% heat-inactivated FBS, 1% of insulin-transferrin-selenium, 100 U/ml penicillin and 100 mg/ml streptomycin. Tet21N cells were grown in RPMI (Roswell Park Memorial Institute) 1640 medium (Invitrogen, Barcelona, Spain) supplemented with 10% heat-inactivated FBS, 25 mM HEPES (Invitrogen), 200 mg/ml geneticin (G418), 0.5 mg/ml amphotericin B, 10 mg/ml hygromycin B, 100 U/ml penicillin and 100 mg/ml streptomycin. All cultures were maintained at 37 1C in a saturated atmosphere of 95% air and 5% CO 2 .
RA differentiation. Induction of differentiation of NBL cell lines was performed as described previously by Encinas et al. 12 Briefly, 6 Â 10 5 cells were seeded in 100 mm culture dishes previously coated with 65 mg/ml type I collagen (BD Biosciences, San Agustin de Guadalix, Spain). All-trans RA was added the next day at a final concentration of 10 mM and maintained during 1, 3 and 5 days.
Sphere formation. SK-N-BE(2), IMR-5 and IMR-32 cells were grown for sphere formation in serum-free neurobasal medium (Invitrogen), supplemented with B27 (Invitrogen), 2 mM L-glutamine (Invitrogen), 20 ng/ml EGF (ProSpec-Tany Technogene Ltd, Ness-Ziona, Israel), 20 ng/ml FGF2 (ProSpec-Tany Technogene Ltd), 20 U/ml penicillin and 20 mg/ml streptomycin.
LFG knockdown. For loss-of-function experiments, two sets of shRNA lentiviral constructs were used: shScr and shLFG were previously described in Fernandez et al. 30 and shScr2 and shLFG2 were purchased from ThermoFisher Scientific (RHS4531-EG23017). Lentiviruses were propagated using standard procedures. Then, cells were fixed with 4% paraformaldehyde and stained with 0.5% crystal violet. Crystals were dissolved in 10% acetic acid and the absorbance was measured at 590 nm.
Migration assays. A suspension of 2.5 Â 10 5 SH-SY5Y NBL cells was added in serum-free media to 8-mm-pore cell culture inserts (Falcon Discovery Labware; BD Biosciences). Cells were incubated for 8 h under standard culture conditions and complete media in the lower part of the chamber. Viable cells that had migrated to the lower transwell chamber were quantified by WST-1 assay (Roche).
Xenografts. A total of 5 Â 10 6 SH-SY5Y-pFLuc cells infected with shScr (n ¼ 10) or shLFG (n ¼ 10) were injected in the flank of female NMRI nude mice in 300 ml of phosphate-buffered saline (PBS) and Matrigel (1 : 1). Tumor growth was measured every 2-3 days using an electronic caliper. At the respective scheduled surgery, 150 mg/kg D-Luciferin substrate (Promega Biotech Iberica, Madrid, Spain) was injected intraperitoneally 5 min before animals were killed. The primary tumor mass was excised and weighted. Lungs were removed to detect distant metastases. Each organ was immersed in a 300 mg/ml D-Luciferin solution in PBS and maintained in cold conditions until ex vivo BLI was performed using the IVIS Spectrum from the CIBER-BBN In Vivo Experimental Platform located at Vall d'Hebron Research Institute (VHIR). mRNA microarray analysis. Expression profiling of triplicate experimental sample groups (shScr versus shLFG) was performed using Affymetrix microarray platform and the GeneChip Human Gene 1.0 ST Array (Affymetrix, Santa Clara, CA, USA). Two hundred nanograms of total RNA was hybridized to the arrays with the GeneChip WT Terminal Labeling and Hybridization Kit (Affymetrix). Chips were processed on an Affymetrix GeneChip Fluidics Station 450 and Scanner 3000 and normalization of the raw data (CEL files) was carried out with Robust Multichip Average algorithm. 52 To filter and perform differential expression analyses, a moderated t-test (Po0.05 a-level) and fold-change thresholding (433% reproducible change) were considered. The functional annotations of resulting gene lists were performed using the Gene Ontology 53 and the KEGG 15, 16 databases. To build the heatmaps, array expression values were normalized to the median and log 2 transformed. Values were converted to color scale using the MultipleExperimentViewer software (TM4 Software Suite, Boston, MA, USA 54 ).
ChIP assays. Details of the MYCN chip experiments, along with validation studies, have been previously published by Murphy et al. 18 Sites of enrichment were identified using the normalized log 2 ratios and the NimbleScan peak finding function.
Statistical analysis. Statistical significance was determined by unpaired t-test or one-way ANOVA when indicated using GraphPad (GraphPad Prism Software, La Jolla, CA, USA). *Po0.05, **Po0.01 and ***Po0.001.
